|Description||BAY 73-6691 is a phosphodiesterase inhibitor selective for the PDE9A subtype under the development of Bayer. It selectively inhibits human PDE9 with IC50 value of 55 nM in vitro.BAY 73-6691 was developed for the treatment of Alzheimer's disease, but pre-clinical research is at an early stage.|
|Synonyms||UNII-80ZTV3INTW; (R)-Bay-73-6691; 1-(2-Chlorophenyl)-6-[(2R)-3,3,3-trifluoro-2-methylpropyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidine-4-one|
|Solubility||DMSO: >20 mg/mL|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator Bayer|
TP-10 is a PDE10A inhibitor with IC50 of 0.8 nM. It has extremely potent PDE10A inhibitory activity and high selectivity against other PDEs. It is active in the...
Mirodenafil is a newly developed oral phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction. It significantly improved ...
PF-04447943 is a potent, selective brain penetrant PDE9 inhibitor (Ki of 2.8, 4.5 and 18 nM) for human, rhesus and rat recombinant PDE9 respectively and high se...
An orally active selective type 5 cGMP phosphodiesterase inhibitor.
Vardenafil HCl Trihydrate
Vardenafil HCl Trihydrate is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively. Vardenafil was co-marketed by Bayer Pharmaceu...
L791943 is a highly potent and metabolically stable PDE4 inhibitor with good in vitro activity (IC50= 4.2 nM). L-791, 943 is potent in vitro and in vivo as demo...
Milrinone is a phosphodiesterase 3 (PDE3) inhibitor with vasodilator properties, used to increase the heart's contractility. It increases erythrocyte cAMP activ...
PDE-9 inhibitor is useful for neurodegenerative diseases.
RPL 554 is a potent and selective PDE3/4 inhibitor for respiratory diseases, particularly in patients with asthma.
Udenafil is an oral PDE5 inhibitor. Udenafil significantly increased cAMP and cGMP levels and were more highly distributed in the prostate than plasma. The T/P ...
Small molecule inhibitor of the KRAS–PDEδ interaction that impairs oncogenic KRAS signalling by altering its localization to endomembranes (in cell Kd value 41 ...
Vardenafil, also called as Levitra and Nuviva, is a phosphodiesterase inhibitor that is selective for PDE5 and PDE1 (IC50 = 0.7 and 180 nM, respectively).
TAK-063 is a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. TAK-063 is currently being evaluated in clinical trials for t...
FR-229934 is a Type 5 cyclic nucleotide phosphodiesterase inhibitor. In Feb 2008, preclinical for Erectile dysfunction in Japan was discontinued.
Sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), is a well-tolerated and highly effective tr...
Mirodenafil dihydrochloride is a newly developed oral phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction.
BRL 50481 is a potent, selective substrate-competitive inhibitor of phosphodiesterase (PDE) 7 (Ki = 180 nM).
This active molecular is a Type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor originated by Chiesi Farmaceutici with IC50 value of 0.026 ± 0.006 nM. CH...
PDE1-IN-2 is an inhibitor of PDE1 that has IC50 values of 6, 140 and 164 nM for PDE1C, PDE1B and PDE1A, respectvely.
PF-8380 blocks inflammation-induced LPA synthesis. PF-8380 works both in vitro and in vivo through direct inhibition of autotaxin. In human whole blood PF-8380 ...